Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate

Sakr, Carine J.; Symons, James M.; Kreckmann, Kim H.; Leonard, Robin C.

doi:10.1136/oem.2008.041582

Cited by 34 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other PFOA-exposed worker studies 30,31 also have not reported any consistent evidence of increased heart disease mortality which is likely because of the healthy worker effect. Two of these studies, 28,31 however, have incorporated internal analyses on the basis of PFOArelated job exposure matrices. Such analyses mitigate the healthy worker effect to some extent.…”

Section: Occupational Studiesmentioning

confidence: 98%

Longitudinal Assessment of Lipid and Hepatic Clinical Parameters in Workers Involved With the Demolition of Perfluoroalkyl Manufacturing Facilities

Olsen

Ehresman

Buehrer

et al. 2012

Journal of Occupational &Amp; Environmental Medicine

View full text Add to dashboard Cite

show abstract

Section: Occupational Studiesmentioning

confidence: 98%

Longitudinal Assessment of Lipid and Hepatic Clinical Parameters in Workers Involved With the Demolition of Perfluoroalkyl Manufacturing Facilities

Olsen

Ehresman

Buehrer

et al. 2012

Journal of Occupational &Amp; Environmental Medicine

View full text Add to dashboard Cite

show abstract

“…The mortality of workers ( n = 6,207) at a DuPont plant using PFOA, who were employed between 1948 and 2002, has been studied by Leonard et al (2008) and Sakr et al (2009). Serum PFOA levels among all workers at this plant in 2004 averaged 240 ng/mL, with an average of 490 ng/mL among workers in the PFOA areas (Sakr et al 2007a).…”

Section: Lipids Uric Acid Diabetes and Cardiovascular And Cerebrovmentioning

confidence: 99%

“…SMRs for ischemic heart disease (IHD) compared with U.S. and state general populations were < 1.0, as might be expected because of the healthy worker effect. Sakr et al (2009) conducted dose–response analyses of these same data using a job–exposure matrix (Kreckmann et al 2009), which used job categories and measured serum levels for 1,000 workers in 2004 to assign all cohort members to four quartiles of cumulative serum PFOA. The mean serum was 231 ng/mL.…”

Section: Lipids Uric Acid Diabetes and Cardiovascular And Cerebrovmentioning

confidence: 99%

Epidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA)

Steenland

Fletcher

Savitz

2010

Environ Health Perspect

556

363

View full text Add to dashboard Cite

Objective and sourcesWe reviewed the epidemiologic literature for PFOA.Data synthesisPerfluorooctanoic acid (PFOA) does not occur naturally but is present in the serum of most residents of industrialized countries (U.S. median, 4 ng/mL). Drinking water is the primary route of exposure in some populations, but exposure sources are not well understood. PFOA has been used to manufacture such products as Gore-Tex and Teflon. PFOA does not break down in the environment; the human half-life is estimated at about 3 years. PFOA is not metabolized in the body; it is not lipophilic. PFOA is not directly genotoxic; animal data indicate that it can cause several types of tumors and neonatal death and may have toxic effects on the immune, liver, and endocrine systems. Data on the human health effects of PFOA are sparse. There is relatively consistent evidence of modest positive associations with cholesterol and uric acid, although the magnitude of the cholesterol effect is inconsistent across different exposure levels. There is some but much less consistent evidence of a modest positive correlation with liver enzymes. Most findings come from cross-sectional studies, limiting conclusions. Two occupational cohort studies do not provide consistent evidence for chronic disease; both are limited by sample size and reliance on mortality data. Reproductive data have increased recently but are inconsistent, and any observed adverse effects are modest.ConclusionsEpidemiologic evidence remains limited, and to date data are insufficient to draw firm conclusions regarding the role of PFOA for any of the diseases of concern.

show abstract

“…As part of this robust data set, the potential association of PFOA exposure with an increased cancer mortality or incidence has been studied in both occupationally exposed (Alexander et al, 2003;Lundin et al, 2009: Alexander andLeonard et al, 2008;Sakr et al, 2007aSakr et al, , 2007bSakr et al, , 2009) and nonoccupationally exposed populations (Erikson et al, 2009), including a population in two counties of Minnesota with Drug and Chemical Toxicology, 2010;33(2): 131-137…”

Section: Introductionmentioning

confidence: 99%

Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years

et al. 2010

Drug and Chemical Toxicology

View full text Add to dashboard Cite

Perfluorooctanoate (PFO) is a perfluorinated carboxylate that is widely distributed in the environment. A 2-year chronic study was conducted in rats fed either 30 or 300 ppm of ammonium perfluorooctanoate (APFO). To investigate the possible relationship of APFO exposure to proliferative mammary lesions, a Pathology Working Group (PWG) review of the original slides was performed. The consensus reached by the PWG was that the incidence of mammary-gland neoplasms was not affected by chronic dietary administration of APFO. Therefore, feeding female rats up to 300 ppm of APFO resulted in no increase in proliferative lesions of the mammary tissue.

show abstract

Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate

Abstract: This exposure-response study shows no convincing evidence of increased IHD mortality risk for APFO-exposed workers at this plant. Further studies evaluating the incidence of IHD are being conducted.

Cited by 34 publications

References 34 publications

Longitudinal Assessment of Lipid and Hepatic Clinical Parameters in Workers Involved With the Demolition of Perfluoroalkyl Manufacturing Facilities

Longitudinal Assessment of Lipid and Hepatic Clinical Parameters in Workers Involved With the Demolition of Perfluoroalkyl Manufacturing Facilities

Epidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA)

Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years

Contact Info

Product

Resources

About